-
1
-
-
84870057403
-
Pharmaco¬logical treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents
-
Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmaco¬logical treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012; 17: 1206-1227.
-
(2012)
Mol Psychiatry
, vol.17
, pp. 1206-1227
-
-
Miyamoto, S.1
Miyake, N.2
Jarskog, L.F.3
Fleischhacker, W.W.4
Lieberman, J.A.5
-
2
-
-
84858391237
-
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizo¬phrenia
-
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizo¬phrenia. Transl Psychiatry 2012; 2: E94.
-
(2012)
Transl Psychiatry
, vol.2
-
-
Leweke, F.M.1
Piomelli, D.2
Pahlisch, F.3
Muhl, D.4
Gerth, C.W.5
Hoyer, C.6
-
4
-
-
0010686493
-
Wong K. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays
-
Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA 1975; 72: 4376-4380.
-
(1975)
Proc Natl Acad Sci USA
, vol.72
, pp. 4376-4380
-
-
Seeman, P.1
Chau-Wong, M.2
Tedesco, J.3
-
5
-
-
79952642829
-
All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors
-
Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci Ther 2011; 17: 118-132.
-
(2011)
CNS Neurosci Ther
, vol.17
, pp. 118-132
-
-
Seeman, P.1
-
6
-
-
33645029075
-
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
-
Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006; 31: 795-803.
-
(2006)
Neuropsychopharmacology
, vol.31
, pp. 795-803
-
-
Long, L.E.1
Malone, D.T.2
Taylor, D.A.3
-
7
-
-
84929295239
-
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
-
Gomes FV, Llorente R, Del Bel EA, Viveros MP, Lopez-Gallardo M, Guimaraes FS. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol. Schizophr Res 2015; 164: 155-163.
-
(2015)
Schizophr Res
, vol.164
, pp. 155-163
-
-
Gomes, F.V.1
Llorente, R.2
Del Bel, E.A.3
Viveros, M.P.4
Lopez-Gallardo, M.5
Guimaraes, F.S.6
-
8
-
-
84868122317
-
Multiple mechanisms involved in the large-spectrum therapeutic potential of canna-bidiol in psychiatric disorders
-
Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of canna-bidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012; 367: 3364-3378.
-
(2012)
Philos Trans R Soc Lond B Biol Sci
, vol.367
, pp. 3364-3378
-
-
Campos, A.C.1
Moreira, F.A.2
Gomes, F.V.3
Del Bel, E.A.4
Guimaraes, F.S.5
-
9
-
-
38349158960
-
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
-
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
-
(2008)
Br J Pharmacol
, vol.153
, pp. 199-215
-
-
Pertwee, R.G.1
-
10
-
-
0021258595
-
Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: Analysis and exam¬ples
-
Seeman P, Ulpian C, Wreggett KA, Wells JW. Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: Analysis and exam¬ples. J Neurochem 1984; 43: 221-235.
-
(1984)
J Neurochem
, vol.43
, pp. 221-235
-
-
Seeman, P.1
Ulpian, C.2
Wreggett, K.A.3
Wells, J.W.4
-
11
-
-
0015861774
-
Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction
-
Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
-
(1973)
Biochem Pharmacol
, vol.22
, pp. 3099-3108
-
-
Cheng, Y.1
Prusoff, W.H.2
-
12
-
-
56549092215
-
Dopamine D2High receptors moderately elevated by bifeprunox and aripiprazole
-
Seeman P. Dopamine D2High receptors moderately elevated by bifeprunox and aripiprazole. Synapse 2008; 62: 902-908.
-
(2008)
Synapse
, vol.62
, pp. 902-908
-
-
Seeman, P.1
-
13
-
-
0002688012
-
Olanzapine binding to dopamine receptors in vitro and in vivoln
-
Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (eds), Eli Lilly, Lippincott Williams & Wilk¬ins: Philadelphia, PA, USA
-
Seeman P, Kapur S. Olanzapine binding to dopamine receptors in vitro and in vivoln: Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (eds). Olanzapine (Zyprexa)—A Novel Antipsychotic. Eli Lilly, Lippincott Williams & Wilk¬ins: Philadelphia, PA, USA, 2000, 3-24.
-
(2000)
Olanzapine (Zyprexa)—A Novel Antipsychotic
, pp. 3-24
-
-
Seeman, P.1
Kapur, S.2
-
14
-
-
0043269348
-
Dopamine displaces [3H]domperidone from high- affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium
-
Seeman P, Tallerico T, Ko F. Dopamine displaces [3H]domperidone from high- affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 2003; 49: 209-215.
-
(2003)
Implications for Human Positron Emission Tomography. Synapse
, vol.49
, pp. 209-215
-
-
Seeman, P.1
Tallerico, T.2
Ko, F.3
-
15
-
-
67650410021
-
Dopamine D2High receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil
-
Seeman P, Guan H-C, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil. Synapse 2009; 63: 698-704.
-
(2009)
Synapse
, vol.63
, pp. 698-704
-
-
Seeman, P.1
Guan, H.-C.2
Hirbec, H.3
-
16
-
-
37249075040
-
Anti-Parkinson therapeutic potencies correlate with their affinities for dopamine D2High receptors
-
Seeman P. Anti-Parkinson therapeutic potencies correlate with their affinities for dopamine D2High receptors. Synapse 2007; 61: 1013-1018.
-
(2007)
Synapse
, vol.61
, pp. 1013-1018
-
-
Seeman, P.1
-
17
-
-
0025876938
-
Effects of cannabidiol in animal models predictive of antipsychotic activity
-
Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991; 104: 260-264.
-
(1991)
Psychopharmacology (Berl)
, vol.104
, pp. 260-264
-
-
Zuardi, A.W.1
Rodrigues, J.A.2
Cunha, J.M.3
-
18
-
-
17444393586
-
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
-
Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005; 512: 199-205.
-
(2005)
Eur J Pharmacol
, vol.512
, pp. 199-205
-
-
Moreira, F.A.1
Guimaraes, F.S.2
-
19
-
-
2442641276
-
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
-
Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 2004; 75: 633-638.
-
(2004)
Life Sci
, vol.75
, pp. 633-638
-
-
Guimaraes, V.M.1
Zuardi, A.W.2
Del Bel, E.A.3
Guimaraes, F.S.4
-
20
-
-
0032577340
-
Complex phar¬macology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain canna- binoid receptors
-
Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC. Complex phar¬macology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain canna- binoid receptors. Life Sci 1998; 63: PL1-PL6.
-
(1998)
Life Sci
, vol.63
, pp. PL1-PL6
-
-
Petitet, F.1
Jeantaud, B.2
Reibaud, M.3
Imperato, A.4
Dubroeucq, M.C.5
-
21
-
-
0022414990
-
The func¬tional state of the dopamine receptor in the anterior pituitary is in the high- affinity form
-
George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The func¬tional state of the dopamine receptor in the anterior pituitary is in the high- affinity form. Endocrinology 1985; 117: 690-697.
-
(1985)
Endocrinology
, vol.117
, pp. 690-697
-
-
George, S.R.1
Watanabe, M.2
Di Paolo, T.3
Falardeau, P.4
Labrie, F.5
Seeman, P.6
-
22
-
-
0021239345
-
Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors
-
McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol Cell Endocrinol 1984; 36: 201-209.
-
(1984)
Mol Cell Endocrinol
, vol.36
, pp. 201-209
-
-
McDonald, W.M.1
Sibley, D.R.2
Kilpatrick, B.F.3
Caron, M.G.4
-
23
-
-
0037255987
-
Pharmacokinetics and pharmacodynamics of cannabinoids
-
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-360.
-
(2003)
Clin Pharmacokinet
, vol.42
, pp. 327-360
-
-
Grotenhermen, F.1
-
24
-
-
40849137554
-
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 hetero- mers. A combined neurochemical and behavioral analysis
-
Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 hetero- mers. A combined neurochemical and behavioral analysis. Neuropharmacology 2008; 54: 815-823.
-
(2008)
Neuropharmacology
, vol.54
, pp. 815-823
-
-
Marcellino, D.1
Carriba, P.2
Filip, M.3
Borgkvist, A.4
Frankowska, M.5
Bellido, I.6
-
25
-
-
58149096475
-
Looking for the role of cannabinoid receptor heteromers in striatal function
-
Ferre S, Goldberg SR, Lluis C, Franco R. Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 2009; 56(Suppl 1): 226-234.
-
(2009)
Neuropharmacology
, vol.56
, pp. 226-234
-
-
Ferre, S.1
Goldberg, S.R.2
Lluis, C.3
Franco, R.4
-
26
-
-
84890068169
-
L-DOPA- treatment in primates disrupts the expression of A(2A) adenosine-CB(1) canna- binoid-D(2) dopamine receptor heteromers in the caudate nucleus
-
Bonaventura J, Rico AJ, Moreno E, Sierra S, Sanchez M, Luquin N et al. L-DOPA- treatment in primates disrupts the expression of A(2A) adenosine-CB(1) canna- binoid-D(2) dopamine receptor heteromers in the caudate nucleus. Neuro¬pharmacology 2014; 79: 90-100.
-
(2014)
Neuro¬pharmacology
, vol.79
, pp. 90-100
-
-
Bonaventura, J.1
Rico, A.J.2
Moreno, E.3
Sierra, S.4
Sanchez, M.5
Luquin, N.6
-
28
-
-
84924993304
-
Dopamine super¬sensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
-
Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, lyo M. Dopamine super¬sensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol 2015; 29: 383-389.
-
(2015)
J Psychopharmacol
, vol.29
, pp. 383-389
-
-
Takase, M.1
Kanahara, N.2
Oda, Y.3
Kimura, H.4
Watanabe, H.5
Lyo, M.6
-
29
-
-
43749124214
-
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
-
Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192: 306-307.
-
(2008)
Br J Psychiatry
, vol.192
, pp. 306-307
-
-
Morgan, C.J.1
Curran, H.V.2
-
30
-
-
72149105357
-
High-potency cannabis and the risk of psychosis
-
Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195: 488-491.
-
(2009)
Br J Psychiatry
, vol.195
, pp. 488-491
-
-
Di Forti, M.1
Morgan, C.2
Dazzan, P.3
Pariante, C.4
Mondelli, V.5
Marques, T.R.6
|